Lloyd Segal

McKinsey & Co., Inc. (Canada) provides management consulting services for private, public, and social sector institutions. The company is headquartered in Toronto, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

LMC Diabetes & Endocrinology Ltd. provides complete care in Diabetes, Endocrinology and Metabolism. It provides information on diabetes prevention, type 1 & diabetes, insulin pump therapy, treatment options and helps to overcome obstacles to meet diabetes targets. The firm enables wellness, embracing learning and expanding the therapeutic horizon is integrated into all aspects of centres. The company was founded by Ronnie Aronson in 1997 and is headquartered in Toronto, Canada.

MedReleaf Corp. engages in the production and sale of medical cannabis products. Its cannabis products include dried, oil, oil capsules, and topical creams. The company was founded by Neil J. Closner and Eitan Popper on February 28, 2013 and is headquartered in Markham, Canada.

Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada.

Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.